Trial Profile
Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Aducanumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ENGAGE
- Sponsors Biogen
- 04 Jan 2024 Results performing genome-wide association studies (GWAS) of ARIA in participants in the ENGAGE and EMERGE trials, published in the Neurology
- 19 Oct 2023 According to Biogen media release, the company will present pooled ENGAGE/EMERGE integrated placebo-controlled period and long-term extension (LTE) topline results at the upcoming Clinical Trials on Alzheimer's Disease (CTAD) meeting taking place October 24-27 in Boston, Mass.
- 20 Jul 2023 Results from GRADUATE 1&2 and CLARITY, EMERGE and ENGAGE assessing Re-estimation of drug-specific amyloid removal parameters and the rate constant for pathogenic tau turnover brings the Q-ATN model presented at the Alzheimer's Association International Conference 2023